Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $100.95 USD
Change Today +0.06 / 0.06%
Volume 285.7K
ASPX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

auspex pharmaceuticals inc (ASPX) Snapshot

Open
$100.92
Previous Close
$100.89
Day High
$100.97
Day Low
$100.92
52 Week High
04/28/15 - $100.99
52 Week Low
05/14/14 - $14.75
Market Cap
3.2B
Average Volume 10 Days
448.7K
EPS TTM
$-2.73
Shares Outstanding
31.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AUSPEX PHARMACEUTICALS INC (ASPX)

Related News

No related news articles were found.

auspex pharmaceuticals inc (ASPX) Related Businessweek News

No Related Businessweek News Found

auspex pharmaceuticals inc (ASPX) Details

Auspex Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing novel medicines for the treatment of orphan diseases. The company’s product candidates are used to address medical needs primarily in hyperkinetic movement disorders, such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome, as well as other orphan indications. Its lead product candidate includes Austedo (SD-809), a final stage development product for the treatment of chorea associated with Huntington’s disease. The company’s other product candidates comprise SD-560, a deuterium-containing form of pirfenidone; SD-254, deuterium-containing form of venlafaxine, which has completed two Phase 1 clinical trial. Auspex Pharmaceuticals, Inc. was founded in 2001 and is headquartered in San Diego, California.

35 Employees
Last Reported Date: 03/16/15
Founded in 2001

auspex pharmaceuticals inc (ASPX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $470.0K
Chief Financial Officer
Total Annual Compensation: $401.7K
Chief Operating Officer
Total Annual Compensation: $420.0K
Chief Medical Officer
Total Annual Compensation: $291.2K
Vice President of Research
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2014.

auspex pharmaceuticals inc (ASPX) Key Developments

Auspex Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited - M&A Call

To discuss the merger agreement with Auspex Pharmaceuticals, Inc

Auspex Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Reaffirms Earnings Guidance for 2015

Auspex Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported operating loss of $20,202,000 compared to $4,908,000 a year ago. Net loss attributable to company shareholders was $20,028,000 or $0.74 per basic and diluted share compared to $7,589,000 or $46 per basic and diluted share a year ago. The results were skewed by an increase in weighted-average common shares outstanding of 27 million from 0.17 million year over year. For the year, the company reported operating loss of $50,256,000 compared to $13,192,000 a year ago. Net loss attributable to company shareholders was $59,574,000 or $2.68 per basic and diluted share compared to $15,629,000 or $371 per basic and diluted share a year ago. The company reiterated its full year 2015 guidance that it provided on January 12, 2015. The company continues to expect that it will incur $85 to $90 million in research and development expense and $25 to $30 million in general and administrative expense in 2015.

Auspex Pharmaceuticals, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Auspex Pharmaceuticals, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ASPX:US $100.95 USD +0.06

ASPX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ASPX.
View Industry Companies
 

Industry Analysis

ASPX

Industry Average

Valuation ASPX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 22.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AUSPEX PHARMACEUTICALS INC, please visit www.auspexpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.